CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma.
CD24
immune checkpoint
immunotherapy
mantle cell lymphoma
phagocytosis
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
19 May 2022
19 May 2022
Historique:
received:
30
04
2022
revised:
12
05
2022
accepted:
17
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
CD24 and its ligand Siglec-10 were described as an innate immune checkpoint in carcinoma. Here, we investigated this axis in B-cell lymphoma by assessing CD24 expression and evaluating pro-phagocytic effects of CD24 antibody treatment in comparison to hallmark immune checkpoint CD47. In mantle cell lymphoma (MCL) and follicular lymphoma patients, high mRNA expression of CD24 correlated with poor overall survival, whereas CD47 expression did not. Conversely, CD24 expression did not correlate with survival in diffuse large B-cell lymphoma (DLBCL), whereas CD47 did. CD24 was also highly expressed on MCL cell lines, where treatment with CD24 antibody clones SN3 or ML5 potently induced phagocytosis, with SN3 yielding >90% removal of MCL cells and triggering phagocytosis of primary patient-derived MCL cells by autologous macrophages. Treatment with CD24 mAb was superior to CD47 mAb in MCL and was comparable in magnitude to the effect observed in carcinoma lines. Reversely, CD24 mAb treatment was less effective than CD47 mAb treatment in DLBCL. Finally, phagocytic activity of clone SN3 appeared at least partly independent of antibody-dependent cellular phagocytosis (ADCP), suggesting CD24/Siglec-10 checkpoint activity, whereas clone ML5 solely induced ADCP. In conclusion, CD24 is an immunotherapeutic target of potential clinical relevance for MCL, but not DLBCL.
Identifiants
pubmed: 35625912
pii: biomedicines10051175
doi: 10.3390/biomedicines10051175
pmc: PMC9138264
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Union , Marie Sklodowska-Curie grant agreement
ID : 813871
Références
BMC Cancer. 2008 Apr 16;8:106
pubmed: 18416826
N Engl J Med. 2018 Nov 01;379(18):1711-1721
pubmed: 30380386
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Front Cell Dev Biol. 2015 Aug 05;3:47
pubmed: 26301220
Cell Mol Life Sci. 2012 Nov;69(22):3863-79
pubmed: 22760497
Cell Mol Immunol. 2010 Mar;7(2):100-3
pubmed: 20154703
Antib Ther. 2020 Apr;3(2):80-94
pubmed: 32421049
J Hematol Oncol. 2020 Jun 17;13(1):79
pubmed: 32552760
Front Immunol. 2018 Oct 22;9:2421
pubmed: 30405620
Hum Reprod. 2008 May;23(5):1053-62
pubmed: 18332088
Int J Mol Sci. 2014 Nov 10;15(11):20538-54
pubmed: 25391041
J Clin Invest. 2018 Dec 3;128(12):5647-5662
pubmed: 30352428
J Exp Clin Cancer Res. 2022 Mar 14;41(1):97
pubmed: 35287686
Semin Immunol. 2015 Aug;27(4):237-48
pubmed: 26561250
iScience. 2020 Jun 26;23(6):101231
pubmed: 32629603
Pharmgenomics Pers Med. 2021 May 25;14:591-599
pubmed: 34079334
Nat Immunol. 2018 Jan;19(1):76-84
pubmed: 29180808
J Immunol. 2001 May 1;166(9):5567-77
pubmed: 11313396
Science. 1991 Jun 21;252(5013):1657-62
pubmed: 2047874
Blood. 2018 Oct 18;132(16):1647-1656
pubmed: 30154113
Front Cell Dev Biol. 2016 Dec 27;4:146
pubmed: 28083532
Front Immunol. 2020 Jul 17;11:1324
pubmed: 32765491
Anal Chem. 2011 Feb 1;83(3):1078-83
pubmed: 21207944
Int J Mol Sci. 2021 May 11;22(10):
pubmed: 34064635
J Biol Chem. 2001 Jan 12;276(2):1071-7
pubmed: 10986279
Nature. 2019 Aug;572(7769):392-396
pubmed: 31367043
Front Genet. 2019 Jun 12;10:560
pubmed: 31244889
J Pers Med. 2021 Jul 27;11(8):
pubmed: 34442367
J Cell Biol. 2003 Dec 8;163(5):1145-55
pubmed: 14662752
J Immunol. 1991 Aug 15;147(4):1412-6
pubmed: 1831224
J Cell Physiol. 2019 Mar;234(3):2134-2142
pubmed: 30317611
Am J Hematol. 2019 Jun;94(6):710-725
pubmed: 30963600
Am J Clin Pathol. 2015 Oct;144(4):642-8
pubmed: 26386086
N Engl J Med. 2006 Jun 8;354(23):2431-42
pubmed: 16760443
Cancer Immunol Res. 2019 Oct;7(10):1663-1671
pubmed: 31409608
Sci Rep. 2017 Oct 23;7(1):13856
pubmed: 29062075
Clin Lab. 2018 Apr 1;64(4):497-505
pubmed: 29739071
Dtsch Med Wochenschr. 2004 Oct 1;129(40):2094-9
pubmed: 15455300
Cancer Res. 2006 Feb 15;66(4):1917-22
pubmed: 16488989
Blood. 1997 Feb 1;89(3):1058-67
pubmed: 9028339
Future Oncol. 2018 Sep;14(21):2179-2188
pubmed: 29667847
J Clin Oncol. 2019 Apr 20;37(12):946-953
pubmed: 30811285
Am J Hematol. 2021 May 1;96(5):617-629
pubmed: 33661537
Cancer Immunol Res. 2018 Oct;6(10):1150-1160
pubmed: 30089638
Mol Cancer Ther. 2021 Jun;20(6):961-974
pubmed: 33850005
Blood. 1998 Nov 1;92(9):3137-47
pubmed: 9787149
Int J Cancer. 2021 Feb 1;148(3):546-559
pubmed: 32790899
Int Immunol. 1995 Oct;7(10):1557-65
pubmed: 8562500
Cancers (Basel). 2021 Apr 18;13(8):
pubmed: 33919517
Eur J Immunol. 1997 Oct;27(10):2524-8
pubmed: 9368605
Science. 2009 Mar 27;323(5922):1722-5
pubmed: 19264983
Lab Invest. 2010 Jul;90(7):1102-16
pubmed: 20351695
Science. 2010 Jan 1;327(5961):46-50
pubmed: 20044567
Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3588-96
pubmed: 23012401
Blood. 2005 Jan 1;105(1):301-7
pubmed: 15345589
Exp Hematol Oncol. 2021 Jun 10;10(1):36
pubmed: 34112250
PLoS One. 2015 Oct 07;10(10):e0139112
pubmed: 26444008
Oncoimmunology. 2018 Dec 11;8(3):1550619
pubmed: 30723582
Front Immunol. 2019 Apr 15;10:792
pubmed: 31037072
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8
pubmed: 23690610
Haematologica. 2022 Mar 01;107(3):690-701
pubmed: 33792219